Cliff Asness’s Neuropace NPCE Stock Holding History

Cliff Asness’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$571K	Buy	35,920 +7,917	+28%	+$127K	﹤0.01%	3330
2026 Q1	$368K	Buy	+28,003	New	+$420K	﹤0.01%	3302

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Cliff Asness's NPCE Position: Q2 2026 in Review

Cliff Asness increased its Neuropace (NPCE) stake by 28% in Q2 2026, buying an estimated $127K and bringing the position to 35,920 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Cliff Asness first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

Cliff Asness held 35,920 shares of Neuropace worth $571K as of Q2 2026.
Cliff Asness bought 7,917 Neuropace shares in Q2 2026, an estimated $127K.
Neuropace made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3330 holding.
Cliff Asness first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.